NasdaqGM:AXSMPharmaceuticals
Axsome Therapeutics (AXSM) Is Up 11.1% After FDA Clears AUVELITY For Alzheimer’s Agitation Treatment
Axsome Therapeutics recently announced that the U.S. FDA has approved AUVELITY, a first-in-class oral NMDA receptor antagonist and sigma-1 agonist, to treat agitation associated with dementia due to Alzheimer’s disease in adults.
This approval expands AUVELITY’s label beyond major depressive disorder into a large, underserved Alzheimer’s agitation population, supported by Phase 3 data and Breakthrough Therapy and Priority Review designations that highlight its differentiated clinical...